Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions
The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is
rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma …
rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma …
ctDNA as a cancer biomarker: A broad overview
LS Pessoa, M Heringer, VP Ferrer - Critical reviews in oncology …, 2020 - Elsevier
Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …
Current and emerging applications of droplet digital PCR in oncology: an updated review
S Olmedillas-López, R Olivera-Salazar… - Molecular Diagnosis & …, 2022 - Springer
In the era of personalized medicine and targeted therapies for the management of patients
with cancer, ultrasensitive detection methods for tumor genotyping, such as next-generation …
with cancer, ultrasensitive detection methods for tumor genotyping, such as next-generation …
[HTML][HTML] Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic …
Background The presence of mutated KRAS (mut KRAS ctDNA) in plasma samples has
been consistently shown to be a negative prognostic indicator in pancreatic cancer (PC) …
been consistently shown to be a negative prognostic indicator in pancreatic cancer (PC) …
[HTML][HTML] Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
V Caputo, F Ciardiello, CM Della Corte… - … of targeted anti-tumor …, 2023 - ncbi.nlm.nih.gov
Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful
tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring …
tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring …
Circulating tumor DNA: an emerging tool in gastrointestinal cancers
Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA in the bloodstream that
has come from primary or metastatic cancer sites. Neoplasm-specific genetic and epigenetic …
has come from primary or metastatic cancer sites. Neoplasm-specific genetic and epigenetic …
Toward personalized nanomedicine: the critical evaluation of micro and nanodevices for cancer biomarker analysis in liquid biopsy
Liquid biopsy for the analysis of circulating cancer biomarkers (CBs) is a major
advancement toward the early detection of cancer. In comparison to tissue biopsy …
advancement toward the early detection of cancer. In comparison to tissue biopsy …
Pancreatic cancer: molecular characterization, clonal evolution and cancer stem cells
E Pelosi, G Castelli, U Testa - Biomedicines, 2017 - mdpi.com
Pancreatic Ductal Adenocarcinoma (PDAC) is the fourth most common cause of cancer-
related death and is the most lethal of common malignancies with a five-year survival rate …
related death and is the most lethal of common malignancies with a five-year survival rate …
Recent discoveries of diagnostic, prognostic and predictive biomarkers for pancreatic cancer
Simple Summary Biomarkers for cancer diagnosis, prognosis and prediction are important
tools and an urgent need in precision medicine for pancreatic cancer. In recent years, many …
tools and an urgent need in precision medicine for pancreatic cancer. In recent years, many …